<DOC>
	<DOC>NCT00037583</DOC>
	<brief_summary>The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>All adult patients with relapsed or refractory AML, as well as younger de novo AML patients are eligible for the study Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study Phase II will only allow enrollment of younger de novo AML AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of greater than 2 months duration De novo patients with M3 AML AML secondary to exposure to chemotherapy or radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Leukemia</keyword>
</DOC>